Mechanism of Action Modelling

Mechanism of Action modelling incorporates additional biological components to describe a drug’s pharmacology compared to traditional PK/PD approaches and is useful to test or support hypotheses on a drug’s mechanistic pathway.


Physiomics has extensive experience of MOA modelling and most of its models incorporate mechanistic components.


Mechanistic or semi-mechanistic PK/PD modelling can be used to:

Support discussions with investors and regulators

Suggest or support combination with other drugs whose mechanisms may be synergistic

Suggest confirmatory studies


Physiomics developed an agent-based model, presented at AACR, that describes how tumour growth will be effected by combination treatment comprising of ionizing radiation and immune checkpoint blockers. This model incorporates the adaptive immune response and interaction between immune species in order to predict the effect on both injected/ irradiated and distant tumours.

Figure from Physiomics’ poster presented at AACR 2021 showing modelling of the abscopal effect on distant tumour after irradiation of primary tumours

Why Partner With Us?

At Physiomics we combine diverse experience with a commitment to quality and scientific curiosity to develop robust and bespoke solutions for every project. We work collaboratively and flexibly to ensure we deliver what our clients need and offer further insight and direction to your project.


To find out more about our collaborations and partnerships, please click here [Partners]

Interested in speaking with a consultant?

We’ll arrange a brief consultation for you with a specialist in our team.